Page 1 | Search Results | Blood | American Society of Hematology

Skip Nav Destination

1-11 of 11

Sort by

Sort Order Select

Journal Articles

Safety of live-attenuated MMR vaccination in patients with multiple myeloma receiving daratumumab after autologous stem cell transplantation

James Davis, Jessica McElwee, Kelley Julian, Victoria Nachar, Jordan Snyder, Zahra Mahmoudjafari, Katelynn Granger, Matthew Warrick, Deidra Smith, Anthony Dominick, Kimberly Green, Shebli Atrash, Douglas Sborov, Grace Elsey, Donald Moore

Blood (2025) 146 (Supplement 1): 408.

https://doi.org/10.1182/blood-2025-408

Published: 2025

Journal Articles

Supportive care alone is effective for managing low-grade CRS in multiple myeloma patients treated with bispecific antibodies

Blood (2025) 146 (Supplement 1): 4579.

https://doi.org/10.1182/blood-2025-4579

Published: 2025

Journal Articles

Dexamethasone for management of cytokine release syndrome (CRS) associated with talquetamab in patients with Relapsed/Refractory multiple myeloma

Blood (2025) 146 (Supplement 1): 720.

https://doi.org/10.1182/blood-2025-720

Published: 2025

Journal Articles

Incidence of CMV-reactivation in multiple myeloma patients receiving bispecific antibodies

Blood (2025) 146 (Supplement 1): 5802.

https://doi.org/10.1182/blood-2025-5802

Published: 2025

Journal Articles

Dexamethasone for the Management of CRS Related to Teclistamab in Patients with Relapsed/Refractory Multiple Myeloma

James A Davis, Jordan Snyder, Mikhaila Rice, Donald C Moore, Christopher Cahoon, Kelley Julian, Charlotte B Wagner, Katelynn Granger, Kimberly M Green, Shebli Atrash, Hailey Hill, Jessica McElwee, Grace Elsey, Jack Khouri, Joslyn Rudoni, Zahra Mahmoudjafari, Victoria Nachar

Blood (2024) 144 (Supplement 1): 2382.

https://doi.org/10.1182/blood-2024-193025

Published: 2024

Journal Articles

Risk Factors for Severe Infection in Patients Receiving Bispecific Antibody Therapies for Lymphoma

Iman Ahmed, Victoria Nachar, Lydia Benitez, Shannon A. Carty, Dahlia Sano, Ryan A. Wilcox, XI Yang, Jonathan Weiss, Yasmin H. Karimi

Blood (2024) 144 (Supplement 1): 3105.

https://doi.org/10.1182/blood-2024-205406

Published: 2024

Journal Articles

Outcomes of Sequenced Therapy in Mantle Cell Lymphoma in Patients Treated with First-Line Autologous Stem Cell Transplantation and Second-Line BTK Inhibitor

Michael McLane, Victoria Nachar, Shannon A. Carty, Mark S Kaminski, Tycel J. Phillips, Dahlia Sano, Jonathan Weiss, Ryan A. Wilcox, Iman Ahmed, Yasmin H. Karimi

Blood (2024) 144 (Supplement 1): 6348.

https://doi.org/10.1182/blood-2024-209170

Published: 2024

Journal Articles

Risk Factors for Cytokine Release Syndrome in Patients Receiving Bispecific Antibodies for B-Cell Lymphoma: A Single-Center, Retrospective Cohort Study

XI Yang, Iman Ahmed, Victoria Nachar, Shannon A. Carty, Ryan A. Wilcox, Jonathan Weiss, Dahlia Sano, Tycel J. Phillips, Yasmin H. Karimi

Blood (2024) 144 (Supplement 1): 4477.

https://doi.org/10.1182/blood-2024-211076

Published: 2024

Journal Articles

Consensus recommendations on the management of toxicity associated with CD3×CD20 bispecific antibody therapy

Blood (2024) 143 (16): 1565–1575.

https://doi.org/10.1182/blood.2023022432

Published: 2024

Journal Articles

Cost Effectiveness of Mosunetuzumab and CAR-T Cell Therapy in Relapsed/Refractory Follicular Lymphoma

Manisha Lin, Jonathan Weiss, Tycel J. Phillips, Dahlia Sano, Shannon A. Carty, Monalisa Ghosh, Iman Ahmed, Victoria Nachar, David Hutton, Yasmin H. Karimi

Blood (2023) 142 (Supplement 1): 256.

https://doi.org/10.1182/blood-2023-182244

Published: 2023

Journal Articles

Risk of Opportunistic Infections in Patients with Bendamustine-Associated Lymphopenia and the Utility of Antimicrobial Prophylaxis

Jayasree Krishnan, MD, Victoria Nachar, PharmD, Bernard Lawrence Marini, PharmD, Anthony J. Perissinotti, PharmD, Tycel J. Phillips, MD, Mark S Kaminski, MD, Shannon A. Carty, MD, Ryan A. Wilcox, MD

Blood (2020) 136 (Supplement 1): 50.

https://doi.org/10.1182/blood-2020-142763

Published: 2020

Update search

NARROW

Publications

Format

Subjects

Article Type

Date

Availability

Safety of live-attenuated MMR vaccination in patients with multiple myeloma receiving daratumumab after autologous stem cell transplantation

Supportive care alone is effective for managing low-grade CRS in multiple myeloma patients treated with bispecific antibodies

Dexamethasone for management of cytokine release syndrome (CRS) associated with talquetamab in patients with Relapsed/Refractory multiple myeloma

Incidence of CMV-reactivation in multiple myeloma patients receiving bispecific antibodies

Dexamethasone for the Management of CRS Related to Teclistamab in Patients with Relapsed/Refractory Multiple Myeloma

Risk Factors for Severe Infection in Patients Receiving Bispecific Antibody Therapies for Lymphoma

Outcomes of Sequenced Therapy in Mantle Cell Lymphoma in Patients Treated with First-Line Autologous Stem Cell Transplantation and Second-Line BTK Inhibitor

Risk Factors for Cytokine Release Syndrome in Patients Receiving Bispecific Antibodies for B-Cell Lymphoma: A Single-Center, Retrospective Cohort Study

Consensus recommendations on the management of toxicity associated with CD3×CD20 bispecific antibody therapy

Cost Effectiveness of Mosunetuzumab and CAR-T Cell Therapy in Relapsed/Refractory Follicular Lymphoma

Risk of Opportunistic Infections in Patients with Bendamustine-Associated Lymphopenia and the Utility of Antimicrobial Prophylaxis

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only